The pathogenesis of lung disease in chroaic berylliosis is pooriy understood; however, immunologic mechanisms have been suggested to play an important role in this disease. The previous immunologic evidence has been laqjely indirect, from studies on skin tests with beryllium salts. We have investigated the role of cellular immune mechanisms in this disease by studying the blast transformation of lymphocytes of these patients (35) in the presence of beryllium sulfate (BeS04) in tissue culture. The control groups included beryllium imlus try workers without disease (30), normal, healthy subjects (22) and patients with other lung diseases (12). The degree of Mast transformation was graded (1+ to 4+) on the basis of morphologic counting of blast cells and, in some cases, also, by the uptake of tritiated thymidine. Circulating serum immunoglobulin levels were also measured. Of the 35 patients with chronic berylliosis, 18 demonstrated a Mast transformation of 4+, three showed 3+, four showed 1+ and 10 were negative. There was also a good correlation between the severity of the clinical disease and the degree of Mast transformation. The incidence of positive results in the control groups was extremely low. The serum IgA level was significantly elevated in 17 patients with berylliiis. At the time of tedhg, all patients with berylliosis were being treated with varying doses of prednisone, and since steroids usually inhibit the Mast transformation response, our finding of a positive reaction in 71 percent of the patients (25 out of 35) lends stroqg evidence for the role of cellular immune mechanisms in this disease.
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pational health hazard. The pathogenesis of the disease is not completely understood and the degree to which both the direct, toxic and immunologic factors contribute is not yet clear. Immunologicmechanisms have long been suggested to play an important role in this disease; however, the previous immunologic evidence has been largely indirect, inconclusive and was obtained primarily for stud--'From the Departments of Immunopathology and Pulmonary Disease, Cleveland Clinic Foundation, Cleveland. Reprint re uests: Dr. Deodhar, Cleveland Clinic, 9500 Euclid Aoenue, CLoeland 44106 munity such as blast transformation of lymphocytes, uptake of tritiated thymidine and, in a few cases, the release of migration inhibitory factor (MIF). In this study 71 percent of the patients with documented chronic berylliosis showed significant positive results and also a good correlation with clinical severity of the disease. Since all of these patients were on treatment with varying doses of steroids (prednisone) these results are especially significant, since steroids are known to inhibit the blast transformation reaction of lymphocytes. The purpose of the present report is to describe the methods used in these in uitro studies, the results obtained in the CHEST, VOL. 63, NO. 3, MARCH, 1973 study group and the various control goups, clinical correlation and to discuss the significance of these findings with respect to the pathogenesis of the disease and possible clinical applications.
The patients studied during this investigation were divided into four gror~ps as follows: Group 1 consisted of 35 patients who had a well estahlislied diagnosis of chronic berylliosis on the basis of clinical, histopathologic and radiologic feah~res, as well as a history of exposure. There were 28 men and seven women in this group with the average age of 45 years ( range of 21 to 8 0 ) . Groups 2, 3 and 4 were control groups arranged in the following manner. Group 2 inclr~ded 30 subjects who had worked in the beryllir~m indr~stry (Bmsh Wellman Company, Elmore, Ohio) for varying periods, ranging from three years to thirty years, but who had no evidence of chronic beryllium disease. G r o~~p 3 included 22 normal, healthy, young adr~lts working in ottr institution and Group 4 contained 12 patients with a variety of other lung diseases (emphysema, sarcoidosis, etc). All patients in Group 1 were receiving varying doses of prednisone at the time of this str~dy. Eighteen patients in Group 1 were also snbjected to beryllir~m sulfate skin patch tests, and the result? of these were graded also on a 1 to 4+ basis.
On the basis of the clinical s t a h~s of the patient, pulmonary disability, histopathologic severity of the disease, radiologic findings and the dosage requirement of steroid for maintenance therapy, each patient was given a clinical grading of the severity of the disease ranging from 1 to 4+.
In Vitro Lymphocyte Transformation with Beryllium Sulfate
From each subject 30 nil of blood was drawn in a heparinized syringe, which was then placed upright at 37°C to allow the red cells to settle. The plasma containing the buffy coat was removed, centrifuged and the resulting pellet of ler~kocytes was washed in Hanks balanced salt solution (HBSS) and the cells were finally resuspended in Spinner modified minimum essential medir~ni containing 15 percent fetal calf serum, 100 pg of penicillin, 100 pg ml of streptomycin and 292 pg/ml of L-glutarnine. The cell count was arranged to a concentration of 1 x lOa/ml. To a 3 ml aliclrlot of the ler~kocyte suspension were added varying a m o~~n t s of beryllium sulfate to final concentrations of 7, 0.7 and 0.07 pg/ml. Control tubes were prepared without the addition of beryllium sulfate. In certain cases beryllium flr~oritle ( ReF2 ) , magnesir~m sulfate ( MgSO1) and sodium sulfate ( Na2SO4 ) were added to test the specificity of the reaction and the concentrations of these agents were similar to those used for Iwryllium sttlfate. The culture tubes were incubated in a CO:! incubator at 37" for six and seven days ant1 each time the cells were centrifuged, fixed in methanolacetic acid ( 3 : 1 ) and finally stained with hlay-GmenwaldGiemsa stain. For each concentration of bewllium sulfate four culture tubes were set up, two being sacrificed on the sixth clay ant1 the remaining two on the seventh day. Percentage blast transformation was determined by morphologic count of 500 lymphocytes per slide. The result of each test was graded by comparing the maximum blast transformation in the beryllium sulfate containing h~b e s to that in the control tr~bes in the following manner. If the ratio of maximum blast transformation in the bewlliuni srdfate tube to that in the control h~h e was less than two. the result was rrraded as negative. If the ratio was two (nearest whole number), it *, was graded as one plus, three as two plus, four as three plus and greater than four as four plus. A typical blast transformation response to beryllium sulfate is shown in Figure 1 .
In certain cases the blast transforn~ation was also evaluated by studying the incorporation of tritiated thymidine in the lynlphocytes. The c u l h~r e conditions were essentially the same as before, but on the fifth day, two microcuries of tritiated thymidine ( s p act five curies/millimole) was added to each culture tube. The cultures were then terminated on the sixth day and on the seventh day by the addition of 0.1 mhl of unlabeled tliymidine followed by centrifugation of the cells and two washings by cold saline. The cells were treated with cold trichloroacetic acid. then solubilized with tetrae t h y l a m m o n i~i hydroxide and finally counted in a liquid scintillation counter. Again, the incorporation of tritiated thymidine in the beryllium sulfate containing culture tubes was compared with that of the control tubes. The overall procedr~re was essentially the same as described by Valentine The results of the lymphocyte blast transformation response to beryllium sulfate are summarized in Table 1 . Of the 35 patients in the beryllium disease group, 21 showed a strongly positive reaction ( 3 to 4 + ), four were weakly positive ( 1 + ) and 10 were negative. Ten patients showed a blast transformation response of greater than 20 percent, with the controls being less than 5 percent. In six patients who had a positive response and five who had a negative response, the blast transformation tests were repeated using equivalent concentrations of beryllium fluoride, and the results were identical CHEST, VOL. 63, NO. 3, MARCH, 1973 Table 2 . It is apparent from the data in Table 2 of MgS04 and Na2S04 and no-blast transformation was observed in these cases. These results also confirmed the previous finding that the blast transformation was indeed related to the beryllium ion and not to the sulfate ion in beryllium sulfate. The incidence of positive results in the three control groups was extremely small with only two of the 30 beryllium industry workers without disease, two of the 22 normal healthy controls and one of the 12 other lung disease controls showing weakly positive results. There was no satisfactory explanation found for the one strongly positive result noted in the normal healthy control group. This subject was later
As mentioned previously, all patients in Group 1 were graded from 1 to 4+ on a clinical evaluation of the severity of the disease, and a similar grading was also assigned for the blast transformation response. For the purposes of comparison, the clinical and laboratory grading were divided into two groups, high activity ( grades 3 to 4 + ) and low activity (grades up to 2+). Of the 35 patients, clinical grading was available in 34, and of these 31 showed a blast transformation response which agreed with the clinical evaluation. In the remaining three the clinical evaluation was that of low activity disease, whereas the blast transformation response was graded as 3 to 4-k. In contrast, the correlation between the clinical severity of the disease and the results of the beryllium sulfate skin patch test were not nearly as good. This comparison was available in 18 patients, and, of these, only eight showed a good correlation.
Serum immunoglobulin Levels
Data on serum immunoglobulin levels were available on 33 patients with chronic beryllium disease. Two patients showed significant elevation (greater than two standard deviations) of IgG and IgA, 13 showed significant elevations of IgA only, two had eIevations of IgA and IgM and three had IgM elevations only. There was no correlation with the blast transformation response nor with the clinical severity of the disease. In seven patients the elevations of serum immunoglobulins (IgA and IgM) were associated with low blast transformation response (less than grade 2 ) and low clinical disease activity (less than grade 2 ) .
DISCUSSION
Lung disease induced by beryllium and its compounds is known to occur both in acute and chronic form and the clinical pathologic features of both of these have been well d~cumented.~ The direct, toxic effect is most likely responsible for the acute form of the disease; however, the pathogenesis of the chronic form is not completely clear. Cellular immunity or delayed hypersensitivity has been implicated in the pathogenesis of the chronic form of the disease, but the evidence so far has been largely indirect and based primarily on considerations such as the insidious nature of the disease, the latent period between exposure and onset of the disease, the histopathology of the lesion, consisting of the beryllium granuloma with mononuclear and lymphocytic infiltrate and finally the positive skin test with beryllium salts observed in some patients. With the recent development of certain in witro methods for studying cellular immunity, such as blast transformation of lymphocytes in the presence of the suspected antigen, and release of MIF, it seemed reasonable to apply these techniques in the study of patients with the chronic disease. In our studies, a significant correlation was observed with 71 percent of the patients showing a positive result, whereas the incidence of positive results was extremely small in the control groups including beryllium industry workers with no disease, other lung disease control and normal healthy adults. Our finding was especially significant, since all patients with the chronic disease were receiving varying doses of prednisone and it is well known that steroids inhibit the blast transformation response of lymphocytes. It would be reasonable to expect, therefore, that in the absence of steroid treatment the results would have been even more significantly positive.
The results of blast transformation as determined by morphologic counting of cells were confirmed by studying the uptake of tritiated thymidine and more recently, in some preliminary studies, we have observed the release of MIF during the interaction of patients' lymphocytes and beryllium sulfate in vitro. In a recent study reported by Hanifin et a1,4 the in vitro blast transformation reaction of lymphocytes with beryllium sulfate or oxide was studied in three normal, nonsensitive subjects and in seven subjects with delayed and granulomatous hypersensitivity to beryllium, and signscant bansformation was observed in all of the seven sensitized, but in none of the three normal subjects. However, it was not stated in this report whether the seven sensitized subjects indeed had clinical chronic beryllium disease and, also, no attempt was made to correlate the clinical findings with the degree of blast transformation. In our study, on the other hand, an excellent correlation was observed between the severity of the clinical disease and the degree of blast transformation. It was also interesting to note that almost all the beryllium industry workers, who had no evidence of chronic disease but who had presumably been exposed to the same conditions as those for the majority of the diseased patients, showed little or no reactivity with beryllium sulfate in vitro. These studies, therefore, lend strong evidence for the existence of cellular immune reactivity to beryllium in patients with the chronic disease and suggest further that these mechanisms may participate in the pathogenesis of the disease.
The in vitro reaction of lymphocytes with beryllium sulfate appears to be specific for the beryllium ions, since a similar response was observed with beryllium fluoride but not with sodium sulfate nor with salts of magnesium, an element which is classified in the same subgroup of the periodic table as beryllium. The in vitro interaction of beryllium ions probably requires prior complexing with some protein to form a hapten-protein antigenic complex followed by reaction with the sensitized lymphocyte. Such complexing of beryllium ions to tissue proteins and its role in granuloma formation has been demonstrated both in vivo and in vitro, in experimental animal^.^^^ The nature of the lung or skin protein responsible for complexing the beryllium ions and induction of delayed hypersensitivity is not known at present. Also, the nature of the protein, in the tissue culture medium, which pre- sumably complexes with beryllium is also not known. The role of this protein would appear to be primarily that of a carrier, since the sensitivity is directed specifically to the beryllium ions.
CHEST
The role of humoral immune mechanisms appears to be much less clear. In a study reported by Resnick et al,' four out of six patients with proved chronic berylliosis were reported to have IgG serum level in concentrations greater than two standard deviations above the normal mean. Two of these patients also had similar elevations of IgA and IgM immunoglobulins. However, the significance of this finding was not completely clear, since a similar increase in concentration of IgG was found in several workers who had had long exposure to beryllium, but who had never developed any evidence of disease. In our study the most noteworthy elevations were in the IgA class, occurring in 17 of the 35 patients with the chronic disease. However, the significance of this finding was also not clear since IgA elevations are known to occur in a variety of disease processes as well as among normal p e r s~n s .~
The demonstration of cellular immune reactions to beryllium ions in patients with chronic beryllium disease has certain important theoretical and practical implications. If these mechanisms are indeed involved in the pathogenesis of the disease, then attempts should be directed toward suppressing these cell mediated reactions (thymus dependent or T-cell immunity). In this respect, further studies on experimental models of beryllium disease, such as those described by Chiappino et alQ and by Vasilevalo should be very useful in developing specific therapeutic approaches to the disease in man. These models should also be useful in further studying the mechanisms of the disease, particularly with respect to correlation with the in vitro cellular immune parameters.
An important practical application of the in uitro tests for cellular immunity to beryllium may be in the clinical differential diagnosis of granulomatous lung disease and perhaps also in the detection of the high risk subjects working in the beryllium industry. With the increasing use of beryllium and its alloys in various industries it will be impossible on a practical level, to totally eliminate all possible contact with this metal or its salts, but at least the detection of the high risk subjects will, in itself, be very helpful in reducing the incidence of this disease. If cellular immune reactions are indeed important in this disease, then the positive reactors among the beryllium industry workers should be followed closely to determine what significance, if any, the positive reactivity has in relation to the possible development of chronic lung disease. Finally, our results suggest that similar in vitro studies may be fruitful in the investigation of other metalinduced delayed hypersensitivity diseases also.
